Symbols / RYTM
RYTM Chart
About
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 6.60B |
| Enterprise Value | 6.43B | Income | -197.71M | Sales | 174.33M |
| Book/sh | 2.23 | Cash/sh | 6.23 | Dividend Yield | — |
| Payout | 0.00% | Employees | 283 | IPO | — |
| P/E | — | Forward P/E | -37.09 | PEG | — |
| P/S | 37.87 | P/B | 44.32 | P/C | — |
| EV/EBITDA | -34.79 | EV/Sales | 36.87 | Quick Ratio | 4.31 |
| Current Ratio | 4.75 | Debt/Eq | 38.25 | LT Debt/Eq | — |
| EPS (ttm) | -3.10 | EPS next Y | -2.67 | EPS Growth | — |
| Revenue Growth | 54.30% | Earnings | 2026-02-26 | ROA | -26.74% |
| ROE | -85.79% | ROIC | — | Gross Margin | 89.40% |
| Oper. Margin | -102.64% | Profit Margin | -110.32% | Shs Outstand | 66.74M |
| Shs Float | 53.93M | Short Float | 11.97% | Short Ratio | 10.39 |
| Short Interest | — | 52W High | 122.20 | 52W Low | 45.91 |
| Beta | 2.04 | Avg Volume | 759.07K | Volume | 221.41K |
| Target Price | $141.80 | Recom | Strong_buy | Prev Close | $98.65 |
| Price | $98.92 | Change | 0.28% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$141.80
Mean price target
2. Current target
$98.56
Latest analyst target
3. DCF / Fair value
$-39.52
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$98.56
Low
$125.00
High
$167.00
Mean
$141.80
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-19 | init | RBC Capital | — → Outperform | $145 |
| 2026-01-20 | main | Wells Fargo | Overweight → Overweight | $145 |
| 2026-01-20 | main | HC Wainwright & Co. | Buy → Buy | $125 |
| 2026-01-09 | main | Needham | Buy → Buy | $148 |
| 2025-12-22 | main | HC Wainwright & Co. | Buy → Buy | $123 |
| 2025-12-17 | main | Guggenheim | Buy → Buy | $140 |
| 2025-12-12 | main | Canaccord Genuity | Buy → Buy | $141 |
| 2025-12-12 | main | Goldman Sachs | Buy → Buy | $157 |
| 2025-12-12 | main | Citizens | Market Outperform → Market Outperform | $167 |
| 2025-12-11 | main | Needham | Buy → Buy | $145 |
| 2025-11-25 | init | Citigroup | — → Buy | $136 |
| 2025-11-10 | main | Canaccord Genuity | Buy → Buy | $114 |
| 2025-11-07 | main | Needham | Buy → Buy | $120 |
| 2025-11-04 | main | Needham | Buy → Buy | $122 |
| 2025-10-17 | main | Goldman Sachs | Buy → Buy | $139 |
| 2025-10-16 | main | Morgan Stanley | Overweight → Overweight | $129 |
| 2025-09-29 | main | HC Wainwright & Co. | Buy → Buy | $110 |
| 2025-09-25 | main | Morgan Stanley | Overweight → Overweight | $122 |
| 2025-09-25 | main | JMP Securities | Market Outperform → Market Outperform | $142 |
| 2025-09-24 | main | Goldman Sachs | Buy → Buy | $138 |
- Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Exploring a 42.11% Upside Potential with a Strong Buy Consensus - DirectorsTalk Interviews Mon, 23 Feb 2026 19
- Is Rhythm Pharmaceuticals (RYTM) Pricing Reflect Multiyear Surge And Recent Rare Disease Progress - simplywall.st ue, 24 Feb 2026 10
- Is RBC’s TRANSCEND-Driven Coverage and FDA Delay Altering The Investment Case For Rhythm (RYTM)? - Sahm Sun, 22 Feb 2026 08
- RBC Capital Initiates Coverage on RYTM with 'Outperform' Rating - GuruFocus hu, 19 Feb 2026 15
- Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: Should You Buy? - Finviz hu, 19 Feb 2026 16
- RBC Capital Initiates Coverage of Rhythm Pharmaceuticals (RYTM) with Outperform Recommendation - Nasdaq hu, 19 Feb 2026 15
- Smith, Rhythm Pharmaceuticals CFO, sells $702k in RYTM stock By Investing.com - Investing.com South Africa Sat, 07 Feb 2026 08
- How The Rhythm Pharmaceuticals RYTM Story Is Shifting With Imcivree Revenue And New Targets - Yahoo Finance Wed, 18 Feb 2026 12
- Prediction: These 3 Stocks Will Crush the Market in 2026 - The Motley Fool Mon, 16 Feb 2026 08
- Insider Sale: Chief Financial Officer of $RYTM Sells 747 Shares - Quiver Quantitative Fri, 06 Feb 2026 08
- Rhythm Pharmaceuticals (Nasdaq: RYTM) sees BMI, hunger drops in PWS Phase 2 trial - Stock Titan hu, 11 Dec 2025 08
- Rhythm Pharma Hits Record High On Unexpected Obesity-Tied Win - Investor's Business Daily hu, 11 Dec 2025 08
- Insider Sell: Hunter Smith Sells Shares of Rhythm Pharmaceuticals Inc (RYTM) - GuruFocus Fri, 20 Feb 2026 04
- Rhythm Pharma (NASDAQ: RYTM) presents 27.1% BMI drop with setmelanotide plus GLP-1 - Stock Titan Mon, 10 Nov 2025 08
- Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Yahoo Finance ue, 28 Oct 2025 07
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 10000 | — | — | MAZABRAUD YANN | Officer | — | 2026-02-13 00:00:00 | D | nan |
| 1 | 7071 | — | Sale at price 96.26 - 104.76 per share. | SMITH HUNTER C | Chief Financial Officer | — | 2026-02-12 00:00:00 | D | 708576.0 |
| 2 | 6628 | — | Sale at price 104.74 - 107.67 per share. | SMITH HUNTER C | Chief Financial Officer | — | 2026-02-05 00:00:00 | D | 702744.0 |
| 3 | 13293 | — | — | CRAMER PAMELA J. | Officer | — | 2026-01-30 00:00:00 | D | nan |
| 4 | 16968 | — | — | SHULMAN JOSEPH J | Chief Technology Officer | — | 2026-01-30 00:00:00 | D | nan |
| 5 | 3613 | — | — | GERMAN CHRISTOPHER PAUL | Officer | — | 2026-01-30 00:00:00 | D | nan |
| 6 | 6663 | — | — | GARFIELD ALASTAIR PH.D. | Officer | — | 2026-01-30 00:00:00 | D | nan |
| 7 | 68713 | — | — | MEEKER DAVID P | Chief Executive Officer | — | 2026-01-30 00:00:00 | D | nan |
| 8 | 26000 | — | — | SMITH HUNTER C | Chief Financial Officer | — | 2026-01-30 00:00:00 | D | nan |
| 9 | 5500 | — | — | MAZABRAUD YANN | Officer | — | 2026-01-30 00:00:00 | D | nan |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 1.87M | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.00 | 0.00 |
| NormalizedEBITDA | -246.99M | -168.46M | -174.25M | -68.45M |
| TotalUnusualItems | 8.90M | |||
| TotalUnusualItemsExcludingGoodwill | 8.90M | |||
| NetIncomeFromContinuingOperationNetMinorityInterest | -260.60M | -184.68M | -181.12M | -69.61M |
| ReconciledDepreciation | 1.56M | 1.76M | 1.67M | 1.16M |
| ReconciledCostOfRevenue | 13.37M | 9.30M | 2.13M | 599.00K |
| EBITDA | -238.09M | -168.46M | -174.25M | -68.45M |
| EBIT | -239.65M | -170.22M | -175.92M | -69.61M |
| NetInterestIncome | -5.89M | 53.00K | -1.17M | 447.00K |
| InterestExpense | 20.60M | 13.89M | 5.20M | 0.00 |
| InterestIncome | 14.71M | 13.95M | 4.03M | 447.00K |
| NormalizedIncome | -267.63M | -184.68M | -181.12M | -69.61M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -260.60M | -184.68M | -181.12M | -69.61M |
| TotalExpenses | 395.63M | 261.79M | 202.79M | 173.21M |
| TotalOperatingIncomeAsReported | -265.50M | -184.36M | -179.16M | -170.06M |
| DilutedAverageShares | 61.00M | 57.67M | 52.12M | 49.60M |
| BasicAverageShares | 61.00M | 57.67M | 52.12M | 49.60M |
| DilutedEPS | -4.34 | -3.20 | -3.47 | -1.40 |
| BasicEPS | -4.34 | -3.20 | -3.47 | -1.40 |
| DilutedNIAvailtoComStockholders | -264.57M | -184.68M | -181.12M | -69.61M |
| NetIncomeCommonStockholders | -264.57M | -184.68M | -181.12M | -69.61M |
| PreferredStockDividends | 3.97M | |||
| NetIncome | -260.60M | -184.68M | -181.12M | -69.61M |
| NetIncomeIncludingNoncontrollingInterests | -260.60M | -184.68M | -181.12M | -69.61M |
| NetIncomeContinuousOperations | -260.60M | -184.68M | -181.12M | -69.61M |
| TaxProvision | 346.00K | 564.00K | 0.00 | 0.00 |
| PretaxIncome | -260.26M | -184.11M | -181.12M | -69.61M |
| OtherIncomeExpense | 11.14M | 190.00K | -790.00K | 100.00M |
| OtherNonOperatingIncomeExpenses | 2.24M | 190.00K | -790.00K | 100.00M |
| GainOnSaleOfSecurity | 8.90M | |||
| NetNonOperatingInterestIncomeExpense | -5.89M | 53.00K | -1.17M | 447.00K |
| InterestExpenseNonOperating | 20.60M | 13.89M | 5.20M | 0.00 |
| InterestIncomeNonOperating | 14.71M | 13.95M | 4.03M | 447.00K |
| OperatingIncome | -265.50M | -184.36M | -179.16M | -170.06M |
| OperatingExpense | 382.26M | 252.48M | 200.66M | 172.61M |
| ResearchAndDevelopment | 237.96M | 134.95M | 108.63M | 104.13M |
| SellingGeneralAndAdministration | 144.30M | 117.53M | 92.03M | 68.49M |
| GrossProfit | 116.76M | 68.13M | 21.50M | 2.56M |
| CostOfRevenue | 13.37M | 9.30M | 2.13M | 599.00K |
| TotalRevenue | 130.13M | 77.43M | 23.64M | 3.15M |
| OperatingRevenue | 130.13M | 77.43M | 23.64M | 3.15M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 62.39M | 59.43M | 56.61M | 50.28M |
| ShareIssued | 62.39M | 59.43M | 56.61M | 50.28M |
| TotalDebt | 3.94M | 1.26M | 1.94M | 2.55M |
| TangibleBookValue | 15.55M | 162.73M | 256.38M | 279.49M |
| InvestedCapital | 21.73M | 169.76M | 264.26M | 284.15M |
| WorkingCapital | 258.68M | 253.06M | 314.43M | 264.96M |
| NetTangibleAssets | 158.38M | 162.73M | 256.38M | 279.49M |
| CapitalLeaseObligations | 3.94M | 1.26M | 1.94M | 2.55M |
| CommonStockEquity | 21.73M | 169.76M | 264.26M | 284.15M |
| PreferredStockEquity | 142.82M | |||
| TotalCapitalization | 164.55M | 169.76M | 264.26M | 284.15M |
| TotalEquityGrossMinorityInterest | 164.55M | 169.76M | 264.26M | 284.15M |
| StockholdersEquity | 164.55M | 169.76M | 264.26M | 284.15M |
| GainsLossesNotAffectingRetainedEarnings | -39.00K | 134.00K | -92.00K | -1.00K |
| OtherEquityAdjustments | -39.00K | 134.00K | -92.00K | -1.00K |
| RetainedEarnings | -1.16B | -894.74M | -710.06M | -528.94M |
| AdditionalPaidInCapital | 1.18B | 1.06B | 974.36M | 813.04M |
| CapitalStock | 142.88M | 59.00K | 56.00K | 50.00K |
| CommonStock | 61.00K | 59.00K | 56.00K | 50.00K |
| PreferredStock | 142.82M | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 227.72M | 162.99M | 118.22M | 45.37M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 112.21M | 107.78M | 78.41M | 1.95M |
| DerivativeProductLiabilities | 0.00 | 1.15M | 1.34M | 0.00 |
| NonCurrentDeferredLiabilities | 108.27M | 106.14M | 75.81M | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 3.94M | 490.00K | 1.26M | 1.95M |
| LongTermCapitalLeaseObligation | 3.94M | 490.00K | 1.26M | 1.95M |
| CurrentLiabilities | 115.52M | 55.20M | 39.81M | 43.43M |
| OtherCurrentLiabilities | 42.05M | 5.41M | 2.42M | 800.00K |
| CurrentDeferredLiabilities | 2.83M | 1.29M | 1.43M | 7.00M |
| CurrentDeferredRevenue | 1.29M | 1.29M | 1.43M | 7.00M |
| CurrentDebtAndCapitalLeaseObligation | 770.00K | 684.00K | 606.00K | |
| CurrentCapitalLeaseObligation | 0.00 | 770.00K | 684.00K | 606.00K |
| PayablesAndAccruedExpenses | 70.64M | 47.74M | 35.27M | 35.02M |
| CurrentAccruedExpenses | 58.31M | 42.85M | 30.48M | 29.28M |
| Payables | 12.33M | 4.88M | 4.80M | 5.74M |
| AccountsPayable | 12.33M | 4.88M | 4.80M | 5.74M |
| TotalAssets | 392.27M | 332.75M | 382.48M | 329.52M |
| TotalNonCurrentAssets | 18.07M | 24.48M | 28.25M | 21.14M |
| OtherNonCurrentAssets | 7.79M | 15.33M | 16.98M | 12.14M |
| GoodwillAndOtherIntangibleAssets | 6.17M | 7.03M | 7.88M | 4.66M |
| NetPPE | 4.11M | 2.12M | 3.38M | 4.33M |
| AccumulatedDepreciation | -4.77M | -4.06M | -3.15M | -2.26M |
| GrossPPE | 8.88M | 6.18M | 6.53M | 6.59M |
| Leases | 2.71M | 2.71M | 2.71M | 2.71M |
| OtherProperties | 3.48M | 781.00K | 1.18M | 1.52M |
| MachineryFurnitureEquipment | 2.69M | 2.69M | 2.65M | 2.37M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 374.20M | 308.27M | 354.24M | 308.39M |
| OtherCurrentAssets | 8.80M | 6.67M | 7.42M | 3.99M |
| PrepaidAssets | 7.58M | 2.26M | 4.39M | 8.40M |
| Inventory | 18.74M | 8.62M | 2.92M | 111.00K |
| FinishedGoods | 10.71M | 2.90M | 195.00K | 111.00K |
| WorkInProcess | 1.25M | 1.10M | 0.00 | 0.00 |
| RawMaterials | 6.78M | 4.62M | 2.72M | 0.00 |
| Receivables | 18.51M | 14.87M | 6.22M | 1.02M |
| AccountsReceivable | 18.51M | 14.87M | 6.22M | 1.02M |
| CashCashEquivalentsAndShortTermInvestments | 320.56M | 275.85M | 333.29M | 294.86M |
| OtherShortTermInvestments | 231.43M | 215.76M | 205.61M | 235.61M |
| CashAndCashEquivalents | 89.14M | 60.08M | 127.68M | 59.25M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -113.88M | -136.20M | -177.71M | -151.44M |
| IssuanceOfCapitalStock | 178.00M | 48.88M | 131.11M | 161.73M |
| CapitalExpenditure | -47.00K | -4.28M | -5.43M | |
| EndCashPosition | 89.60M | 60.41M | 128.00M | 59.58M |
| BeginningCashPosition | 60.41M | 128.00M | 59.58M | 101.26M |
| EffectOfExchangeRateChanges | 2.00K | -142.00K | 0.00 | 0.00 |
| ChangesInCash | 29.19M | -67.45M | 68.43M | -41.68M |
| FinancingCashFlow | 191.24M | 74.37M | 213.83M | 166.48M |
| CashFlowFromContinuingFinancingActivities | 191.24M | 74.37M | 213.83M | 166.48M |
| NetOtherFinancingCharges | -4.00M | 16.97M | 72.34M | |
| ProceedsFromStockOptionExercised | 17.25M | 8.52M | 10.38M | 4.75M |
| NetPreferredStockIssuance | 138.85M | 0.00 | 0.00 | |
| PreferredStockIssuance | 138.85M | 0.00 | 0.00 | |
| NetCommonStockIssuance | 39.15M | 48.88M | 131.11M | 161.73M |
| CommonStockIssuance | 39.15M | 48.88M | 131.11M | 161.73M |
| InvestingCashFlow | -48.17M | -5.67M | 28.03M | -62.16M |
| CashFlowFromContinuingInvestingActivities | -48.17M | -5.67M | 28.03M | -62.16M |
| NetOtherInvestingChanges | -40.50M | -5.67M | ||
| NetInvestmentPurchaseAndSale | -7.67M | 49.00K | 32.31M | -163.72M |
| SaleOfInvestment | 260.64M | 354.97M | 284.25M | 361.25M |
| PurchaseOfInvestment | -268.31M | -354.92M | -251.94M | -524.97M |
| NetBusinessPurchaseAndSale | 0.00 | 0.00 | 100.00M | |
| SaleOfBusiness | 0.00 | 0.00 | 100.00M | |
| NetIntangiblesPurchaseAndSale | 0.00 | 0.00 | -4.00M | 2.00M |
| SaleOfIntangibles | 0.00 | 0.00 | 7.00M | |
| PurchaseOfIntangibles | 0.00 | 0.00 | -4.00M | -5.00M |
| NetPPEPurchaseAndSale | 0.00 | -47.00K | -281.00K | -434.00K |
| PurchaseOfPPE | 0.00 | -47.00K | -281.00K | -434.00K |
| OperatingCashFlow | -113.88M | -136.16M | -173.43M | -146.00M |
| CashFlowFromContinuingOperatingActivities | -113.88M | -136.16M | -173.43M | -146.00M |
| ChangeInWorkingCapital | 10.57M | 4.81M | -17.41M | 1.90M |
| ChangeInOtherWorkingCapital | -148.00K | -6.61M | ||
| ChangeInOtherCurrentAssets | 7.94M | 1.66M | -4.84M | -11.81M |
| ChangeInPayablesAndAccruedExpense | 21.92M | 14.77M | 1.54M | 18.31M |
| ChangeInPayable | 21.92M | 14.77M | 1.54M | 18.31M |
| ChangeInAccountPayable | 21.92M | 14.77M | 1.54M | 18.31M |
| ChangeInPrepaidAssets | -5.52M | 2.88M | 498.00K | -3.34M |
| ChangeInInventory | -10.12M | -5.71M | -2.81M | -11.00K |
| ChangeInReceivables | -3.65M | -8.64M | -5.20M | -1.25M |
| ChangesInAccountReceivables | -3.65M | -8.64M | -5.20M | -1.25M |
| OtherNonCashItems | 113.39M | 19.43M | 5.12M | -250.00K |
| StockBasedCompensation | 39.68M | 32.55M | 19.83M | 20.80M |
| AmortizationOfSecurities | -8.16M | -9.84M | -2.31M | 0.00 |
| DepreciationAmortizationDepletion | 1.56M | 1.76M | 1.67M | 1.16M |
| DepreciationAndAmortization | 1.56M | 1.76M | 1.67M | 1.16M |
| OperatingGainsLosses | -10.32M | -190.00K | 790.00K | -100.00M |
| GainLossOnInvestmentSecurities | -10.32M | -190.00K | 790.00K | |
| GainLossOnSaleOfBusiness | 0.00 | 0.00 | -100.00M | |
| NetIncomeFromContinuingOperations | -260.60M | -184.68M | -181.12M | -69.61M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for RYTM
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|